Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Top 5 Marijuana Stocks for 2019
With individual stock selection now more critical than ever, this report is designed to bring you some of our top ideas in the marijuana industry this year.
One of the companies highlighted in this report offers a life-changing therapy that reduces the number of seizures in children with two rare types of childhood-onset epilepsy. It has the potential for the stock to sky-rocket. You need to find out the name of this company before the rest of the market does.
P.S. Not many retail investors pay attention to the marijuana sector. Use this complimentary guide and get a head start on your path to profiting from the booming cannabis industry!
Menu

Vanda Pharmaceutical (VNDA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 911,250
  • Shares Outstanding, K 52,643
  • Annual Sales, $ 193,120 K
  • Annual Income, $ 25,210 K
  • 60-Month Beta 0.51
  • Price/Sales 4.58
  • Price/Cash Flow 31.27
  • Price/Book 3.20

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 0.00
  • Number of Estimates 2
  • High Estimate 0.02
  • Low Estimate -0.01
  • Prior Year 0.06
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.13 +4.90%
on 04/18/19
18.98 -10.85%
on 04/05/19
-0.67 (-3.81%)
since 03/22/19
3-Month
16.13 +4.90%
on 04/18/19
29.95 -43.51%
on 01/25/19
-11.95 (-41.39%)
since 01/24/19
52-Week
13.88 +21.95%
on 05/01/18
33.44 -49.40%
on 12/03/18
+2.32 (+15.89%)
since 04/24/18

Most Recent Stories

More News
Earnings Preview: Vanda Pharmaceuticals (VNDA) Q1 Earnings Expected to Decline

Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

VNDA : 16.86 (-2.60%)
VANDA FRIDAY DEADLINE: Rosen Law Firm Reminds Vanda Pharmaceuticals Inc. Investors of Important April 26th Deadline in First-Filed Case - VNDA

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Vanda Pharmaceuticals Inc. from November 4, 2015 through February 11, 2019, inclusive (the "Class Period") of...

VNDA : 16.86 (-2.60%)
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of AMRN, VNDA, WTW and APYX

The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request...

APYX : 4.32 (+4.85%)
AMRN : 18.46 (+0.38%)
WTW : 19.07 (-2.41%)
VNDA : 16.86 (-2.60%)
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Vanda Pharmaceuticals Inc.

Glancy Prongay & Murray LLP ("GPM") reminds investors of the April 26, 2019deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Vanda...

VNDA : 16.86 (-2.60%)
Vanda Pharmaceuticals to Announce First Quarter 2019 Financial Results on May 1, 2019

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2019 on Wednesday, May 1, 2019, after the market closes.

VNDA : 16.86 (-2.60%)
SHAREHOLDER ALERT: VNDA SYNH WSR FSNN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request...

SYNH : 46.28 (-1.39%)
WSR : 12.54 (+1.54%)
FSNN : 0.18 (-10.00%)
VNDA : 16.86 (-2.60%)
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vanda Pharmaceuticals, Syneos, Weight Watchers, and Mattel and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Vanda Pharmaceuticals Inc., Syneos Health, Inc., Weight Watchers International,...

MAT : 12.50 (+2.38%)
SYNH : 46.28 (-1.39%)
WTW : 19.07 (-2.41%)
VNDA : 16.86 (-2.60%)
A Securities Class Action Has Been Filed Against Vanda; Block & Leviton LLP Encourages Shareholders to Contact the Firm

Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, informs investors that there has been a class action lawsuit filed against Vanda Pharmaceuticals...

VNDA : 16.86 (-2.60%)
CLASS ACTION UPDATE for T, VNDA, EB and CRCM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have...

T : 30.58 (-4.74%)
CRCM : 16.50 (+1.35%)
VNDA : 16.86 (-2.60%)
EB : 22.63 (+4.67%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA

Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals, Inc. ("Vanda" or the "Company") (NASDAQ: VNDA). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com...

VNDA : 16.86 (-2.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade VNDA with:

Business Summary

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics...

See More

Key Turning Points

2nd Resistance Point 17.78
1st Resistance Point 17.55
Last Price 16.86
1st Support Level 16.94
2nd Support Level 16.56

See More

52-Week High 33.44
Fibonacci 61.8% 25.97
Fibonacci 50% 23.66
Fibonacci 38.2% 21.35
Last Price 16.86
52-Week Low 13.88

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar